New treatment options for hypertension: An Analytical Report on Emerging Pharmacological and Procedural Interventions

Recent clinical developments have introduced several new treatment options for hypertension, targeting biological pathways that were previously unaddressed by traditional medications. With approximately 1.4 billion people worldwide living with high blood pressure, and nearly half of those in the United States struggling with uncontrolled levels despite taking multiple medications, the demand for innovative therapeutic classes is significant 1. These emerging interventions include highly selective aldosterone synthase inhibitors, long-acting small interfering RNA agents, and advanced endothelin receptor antagonists, all of which aim to reduce the risk of cardiovascular disease and premature death associated with persistently elevated blood pressure 1.

Aldosterone Synthase Inhibition: The Arrival of Baxdrostat

One of the most significant shifts in hypertension management is the introduction of aldosterone synthase inhibitors (ASIs). Baxdrostat, marketed under the name Baxfendy, represents a first-in-class treatment approved for adults whose blood pressure is not adequately controlled with standard therapies 1. Unlike older medications that may have lacked selectivity, baxdrostat is a highly selective oral small molecule that targets the enzyme responsible for producing aldosterone. Aldosterone is a hormone that regulates salt and water retention, and its overproduction is a primary driver of resistant hypertension 2. In the Phase III BaxHTN clinical trial, baxdrostat demonstrated a statistically significant reduction in seated systolic blood pressure. Patients receiving 1 mg doses saw a mean reduction of 14.5 mmHg, while those on 2 mg doses experienced a reduction of 15.7 mmHg, compared to a 5.8 mmHg drop in the placebo group 2.

Clinical observations suggest that this new way of lowering blood pressure could be vital for the estimated 50 percent of hypertensive patients in the United States who fail to reach targets on background regimens including diuretics, ACE inhibitors, or calcium channel blockers 1. The medication is typically used as an add-on therapy and has been generally well tolerated in global trials involving nearly 800 patients 5. Because this class specifically inhibits the production of aldosterone at its source, it provides a distinct mechanism from mineralocorticoid receptor antagonists (MRAs), which only block the receptor rather than reducing the hormone levels themselves 10.

RNA Interference and Long-Acting Injectables: Zilebesiran and Tonlamarsen

Another frontier in hypertension research involves silencing the genetic precursors of blood pressure regulation. Zilebesiran is an investigational RNA interference (RNAi) therapeutic that targets the messenger RNA (mRNA) of angiotensinogen in the liver 3. This process effectively halts the production of angiotensinogen, leading to a durable suppression of the renin-angiotensin-aldosterone system (RAAS). Early Phase I and II trials, such as the KARDIA studies, indicate that a single subcutaneous injection can lead to a greater than 90 percent reduction in circulating angiotensinogen and a reduction in 24-hour systolic blood pressure ranging from 10 to 27 mmHg 3. This sustained effect can last for up to six months, potentially addressing the common clinical issue of patient non-adherence to daily oral regimens 3.

Similarly, researchers are evaluating tonlamarsen, another injectable agent that targets blood pressure regulators. In the Phase 2 Kardinal trial, a once-monthly injection was shown to successfully lower levels of angiotensinogen, which helps regulate pressure by constricting blood vessels and triggering sodium intake 7. These long-acting therapies are particularly relevant for patients with resistant hypertension, defined as blood pressure that remains high despite the use of three or more medications of different classes 6. Other experimental siRNA drugs, such as YKYY029, have also received regulatory clearance for initial human testing to determine their potential in managing stubborn cases 26.

Targeting the Endothelin Pathway with Aprocitentan

For over three decades, no new systemic pathways for hypertension had been successfully targeted until the approval of endothelin receptor antagonists for this indication. Aprocitentan, sold as JERAYGO, is the first dual endothelin receptor antagonist (ERA) approved for treating resistant hypertension in combination with other antihypertensive products 6. The endothelin pathway is a fundamental driver of disease progression, often contributing to vascular constriction and target organ damage. Clinical data from the PRECISION study showed that aprocitentan not only lowers blood pressure but also significantly reduces albuminuria, a biomarker of kidney damage 8. This makes it a relevant option for patients who also suffer from chronic kidney disease 8.

Comparative Clinical Metrics of Emerging Therapies

The following table summarizes the clinical efficacy metrics and mechanisms of action for three prominent new and investigational treatment options for hypertension based on recent trial data.

In addition to these focused therapies, researchers are exploring direct renin inhibitors like sitokiren (SPH3127). In a Phase III trial, sitokiren showed high plasma renin activity inhibition of 83 percent and a reduction in diastolic blood pressure of approximately 8.17 mmHg at a 100 mg dosage 4. These developments illustrate a broader trend toward precision medicine where the specific hormonal or physiological driver of a patient’s hypertension can be targeted directly 27.

Procedural Interventions and Device-Based Therapies

When pharmacological options are insufficient or limited by side effects, device-based treatments such as renal denervation (RDN) have become accessible in several regions. The Paradise Ultrasound Renal Denervation system is one such technology that uses ultrasound energy to reduce the overactivity of sympathetic nerves surrounding the renal arteries 16. This procedure is specifically indicated for patients with resistant hypertension whose levels stay above target despite using at least three antihypertensive medications, including a diuretic 16. By physically modulating the nerve signals that contribute to high blood pressure, these procedures offer a non-drug alternative or adjunct for long-term management 16.

Furthermore, diagnostic innovations are improving the way physicians select these treatments. For instance, radiodiagnostics such as Ga-PentixaFor are being evaluated in Phase 3 studies to improve the diagnostic pathway for treatment-resistant hypertension and primary aldosteronism 25. By identifying specific subtypes of the disease through PET/CT imaging, healthcare providers can better guide the most appropriate therapy for each individual 25.

Clinical Considerations and Risk Management

While the introduction of new treatment options for hypertension provides more tools for management, their implementation requires careful monitoring of patient-specific factors. For example, direct-acting peripheral vasodilators like minoxidil, now available in lower 2.5 mg doses for better titration, require precise adjustment based on patient response and targets to avoid complications 9. Additionally, while blood pressure control is essential for protecting the kidneys, some studies suggest that certain older classes of medication, such as dihydropyridine calcium-channel-blockers, might be associated with a higher risk of adverse kidney events in specific populations, such as those with type 2 diabetes 30.

The management of hypertension is also increasingly focused on comorbidities. Triple-combination therapies that combine antihypertensive agents with lipid-lowering drugs, such as Kanarbzet (fimasartan, atorvastatin, and ezetimibe), are being used to address both high blood pressure and dyslipidemia simultaneously 18. This approach aims to improve medication adherence and reduce the overall cardiovascular risk in high-risk patients. Despite the efficacy of these new treatments, ongoing regulatory oversight and long-term safety studies remain critical to understanding their role within current standard-of-care protocols 12.

Sources

1. Medical Update Online
2. The Cardiology Advisor
3. Springer Nature - The Egyptian Heart Journal
4. Springer Nature - Drugs
5. ScienceDaily
6. BioSpace
7. Cleveland Clinic Newsroom
8. GlobeNewswire
9. Seoul Economic Daily
10. GP Voice
11. The Cardiology Advisor (Lorundrostat)
12. DelveInsight
13. Neurology Advisor
14. Medical Dialogues
15. Gulf News
16. Bastille Post
17. Hypertension (Journal)
18. Korea Biomedical Review
19. Medical Daily
20. NewTimeSpace
21. PR Newswire
22. Current Hypertension Reports
23. MRIKPA
24. Seoul National University
25. BioSpace (Pentixapharm)
26. Fineline Cube
27. Middle East News 247
28. Xi'an Jiaotong University
29. Finance 360
30. Health Care Today